Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol - Full Text View

Sponsor:	Sunovion
Information provided by:	Sunovion
ClinicalTrials.gov Identifier:	NCT00685425

Purpose

The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma

Condition	Intervention	Phase
Asthma Bronchoconstriction	Drug: Levalbuterol HFA MDI Drug: Racemic Albuterol	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Dose Response and PharmacoDynamic Study of Levalbuterol and Racemic Albuterol HFA MDI in Subjects Twelve Years of Age and Older With Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma Exercise and Physical Fitness

Drug Information available for: Albuterol Levalbuterol hydrochloride Albuterol sulfate Levalbuterol tartrate

U.S. FDA Resources

Further study details as provided by Sunovion:

Primary Outcome Measures:

FEV1 AUC 0-60 (% decrease from post-dose/pre-challenge FEV1) [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Maximum percent decrease in FEV1 from visit post-dose/pre-challenge FEV1 [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
Minimum percent change in FEV1 from visit pre-dose FEV1. [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
time to recovery (min), Protected/Unprotected Subjects Counts [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
FVC AUC 0-60 (% decrease from post-dose/pre-challenge FEV1). [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
Maximum percent decrease in FVC from visit post-dose/pre-challenge FVC, [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
Minimum percent change in FVC for pre-dose FVC, [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
FEF25-75% AUC 0-60 (% decrease from post-dose/pre-challenge FEV1), [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
Maximum percent decrease in FEF25-75% from visit post-dose/pre-challenge FEF25-75% [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]
Minimum percent change in FEF25%-75% from visit pre-dose FEF25-75%. [ Time Frame: Days -7, 0, 5, 10, 15 ] [ Designated as safety issue: No ]

Enrollment:	62
Study Start Date:	October 2002
Study Completion Date:	March 2003
Primary Completion Date:	March 2003 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: A Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.	Drug: Levalbuterol HFA MDI levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Arm #A Xopenex HFA MDI
Active Comparator: B Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.	Drug: Racemic Albuterol racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Arm #B Proventil HFA MDI

Arms

Assigned Interventions

Experimental: A

Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.

Drug: Levalbuterol HFA MDI

levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).
Arm #A
Xopenex HFA MDI

Active Comparator: B

Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.

Drug: Racemic Albuterol

racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).
Arm #B
Proventil HFA MDI

Detailed Description:

A randomized, modified-blind, active controlled, multicenter, parallel treatment, 3x3 dose level crossover study evaluating the dose response of levalbuterol in subjects 12 years of age and older with exercise induced bronchoconstriction. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject, male or female, must be at least 12 years of age at the time of consent.
Female subjects 12-60 years of age must have a negative serum pregnancy test.
Women of child bearing potential must be using an acceptable method of birth control throughout the study.
Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start
Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.
Subject must have a chest X-ray for the study or within 12 months prior to randomization.
Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.

Exclusion Criteria:

Female subject who is pregnant or lactating.
Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.
Subject whose schedule prevents him or her from starting study visits before 12 PM.
Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.
Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.
Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.
Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.
Subject using any prescription drug with which albuterol sulfate administration is contraindicated.
Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.
Subject with a history of cancer (exception: basal cell carcinoma in remission).
Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.
Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.
Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.
Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.
Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.
Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.
Subject who is a staff member or relative of a staff member.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685425

Locations

United States, California

Los Angeles, California, United States

Signal Hill, California, United States
United States, Colorado

Denver, Colorado, United States
United States, Minnesota

Minneapolis, Minnesota, United States
United States, Virginia

Burke, Virginia, United States

Sponsors and Collaborators

Sunovion

More Information

No publications provided

Responsible Party:	Xopenex Medical Director, Sunovion Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:	NCT00685425 History of Changes
Other Study ID Numbers:	051-308
Study First Received:	May 23, 2008
Last Updated:	November 1, 2010
Health Authority:	United States: Food and Drug Administration

Keywords provided by Sunovion:

Asthma
Exercised induced bronchoconstriction

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Albuterol
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs

Pharmacologic Actions
Therapeutic Uses
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on February 09, 2012